# Welcome to the European VC Podcast with Frederik Groenewegen
In this episode of the European VC podcast, we welcome Frederik Groenewegen, Co-Founder and General Partner of 415 CAPITAL – an innovative capital firm that invests in medical technology companies. Frederik has extensive experience in Venture Capital and has been an investor in over a dozen innovative medical tech companies. He currently serves as a Board Director at Cardiac Success and R3 Vascular.
## What you’ll learn
In this podcast, Frederik shares the story behind the creation of 415 Capital. He talks about how his family’s experience and background in MedTech led them to start the capital firm. Frederik also explains how 415 Capital leverages a proprietary commercialization and distribution platform to win the best deals. Further, he shares his insights on what he has learned from Fund I and how the 415 Capital team is adapting for Fund II. Finally, Frederik gives his thoughts on COVID and its impact on the MedTech space.
Listen to the full podcast to hear more about Frederik’s experience and insights on Venture Capital.
capital, eu, european, euvc, frederik, groenewegen, investing, investment, investments, podcast, spreaker, startup, tech, theeuropeanvc, vc, venture, venturecapital, ventures
## About the Source
This podcast was originally published on the [European VC podcast](https://www.spreaker.com/user/euvc/euvc-frederik-master-v2) hosted by the European Venture Capital – the go-to podcast for everything European VC.
_”The European Venture Capital podcast is the go-to show for everything VC in Europe. Each week, we interview the best VCs interwoven with educational segments delivered by our in-house team of experts.”_
Today we are happy to welcome Frederik Groenewegen, Co-Founder and General Partner of 415 CAPITAL. He has been an investor in more than a dozen of innovative medical technology companies and currently serves as a Board Director at Cardiac Success and R3 Vascular.
In this episode you’ll learn:
– How Frederik and his family’s experience and position in MedTech led them to building 415 Capital
– How 415 Capital is leveraging a proprietary commercialization and distribution platform to win the best deals
– What Frederik has learnt from Fund I and how the team is adapting for Fund II
– How Frederik thinks about COVID as well as the current market’s impact on the MedTech space